Clinical Outcomes of Stereotactic Body Radiotherapy for Early-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Study
Background Small-cell lung cancer (SCLC) is an aggressive malignancy with early metastatic potential. Although surgery plus chemotherapy is standard for early-stage disease, many patients are not surgical candidates. Stereotactic body radiotherapy (SBRT) has emerged as a potential alternative in this setting. We report single-institution outcomes and toxicity of SBRT in early-stage SCLC. Methodology We retrospectively reviewed patients with histologically confirmed T1-T2N0 SCLC treated with curative-intent SBRT, regardless of fractionation, between 2018 and 2023. The primary endpoint was locoregional control (LRC); secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. Survival was analyzed using Kaplan-Meier estimates and log-rank tests; LRC was estimated using cumulative incidence, with death as a competing event. Results In total, 12 patients were included, with a median age of 76.5 years; nine (75.0%) were male, nine (75.0%) had peripheral tumors, and seven (58.3%) received chemotherapy. At a median follow-up of 20.6 months, median OS was 48.2 months (95% confidence interval (CI): 6.0-90.5), median PFS was 19.0 months (95% CI: 0.0-42.8), and median LRC was not reached, with a two-year LRC rate of 80%. Distant metastases occurred in seven (58.3%) patients and locoregional recurrence in three (25.0%), and no grade ≥2 toxicities were observed. In exploratory subgroup analyses, survival was numerically longer with chemotherapy (p = 0.281), peripheral tumors (p = 0.066), ECOG performance status 0-1 (p = 0.284), and tumors <3 cm (p = 0.350), although none of these differences were statistically significant. Conclusions In this small retrospective cohort, SBRT was feasible and was associated with encouraging locoregional control and no documented grade ≥2 toxicity in patients with medically inoperable early-stage SCLC. These preliminary, hypothesis-generating findings warrant validation in multicenter collaborative studies and prospective registries.
Authors
- Joana Cardia
- Isabel Rodrigues (ORCID: https://orcid.org/0000-0001-8898-868X)
- João Basílio
- Susana Costa
- Tiago Figueiredo
- João Lima
Publication Details
- Journal
- Cureus
- Published
- 2026-11-21
- DOI
- https://doi.org/10.7759/cureus.120032
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00